Search

Your search keyword '"Richard Elion"' showing total 65 results

Search Constraints

Start Over You searched for: Author "Richard Elion" Remove constraint Author: "Richard Elion"
65 results on '"Richard Elion"'

Search Results

1. Changes in weight and BMI with first-line doravirine-based therapy

2. Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV preexposure prophylaxis

3. Brief Report: Durability of the Effect of Financial Incentives on HIV Viral Load Suppression and Continuity in Care: HPTN 065 Study

4. Patterns and Correlates of Participant Retention in a Multi-City Pre-Exposure Prophylaxis Demonstration Project

5. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project

6. Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen

7. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

8. LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)

9. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing

10. Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States

11. 1704. Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) among People Living with Human Immunodeficiency Virus (PLWH)

13. Effet de la doravirine sur le poids et l’indice de masse corporelle chez les adultes VIH-1 débutant un traitement antirétroviral

14. The preexposure prophylaxis revolution

15. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

16. Sorting Through the Lost and Found

17. High Interest in Preexposure Prophylaxis Among Men Who Have Sex With Men at Risk for HIV Infection

18. Recent abacavir use increases risk of type 1 and type 2 myocardial infarctions among adults with HIV

19. Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients: A Randomized Clinical Trial (HPTN 065)

20. Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy

21. 550. Adherence and Persistency With Modern Single vs. Multi-Tablet Antiretroviral (ARV) Regimens in First Treatment of HIV in Clinical Practice

22. 2553. Addressing Knowledge and Practice Gaps in HIV Management with Engaging Continuing Education

23. Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV-1-Infected Patients with HIV-1 RNA <= 100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis

24. Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies

25. Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population

26. Disparities in Achieving and Sustaining Viral Suppression among a Large Cohort of HIV-Infected Persons in Care Washington, DC

27. 1320. Continuing Education Improves HIV Screening and Use of PrEP in High-Risk Patients

28. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study

29. Simplified Maintenance Therapy With Abacavir/Lamivudine and Atazanavir After Discontinuation of Ritonavir

30. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir

31. HIV Policy: The Path Forward—A Joint Position Paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians

32. Efficacy and Safety of Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate in HIV-infected, Virologically Suppressed Black and Non-Blacks Adults Through Week 48: Subgroup Analysis of a Randomized Switch Study

33. Authors' Reply: Race and the Public Health Impact Potential of Pre-Exposure Prophylaxis in the United States

34. Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

35. Once-daily antiretroviral therapies for HIV infection: Consensus statement of an Advisory Committee of the International Association of Physicians in AIDS Care

36. Weight Loss as a Predictor of Survival and Disease Progression in HIV Infection

37. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results

38. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

39. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

40. The Prevalence of Rectal, Urethral, and Pharyngeal Neisseria gonorrheae and Chlamydia trachomatis among Asymptomatic Men Who Have Sex with Men in a Prospective Cohort in Washington, D.C

41. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)

42. Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use

43. Update on antiretroviral therapy: the 15th CROI

44. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services

45. Recent developments in HIV therapeutics

46. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study

47. 007.5 Sexual risk behaviour and sexually transmitted diseases among men who have sex with men participating in a pre-exposure prophylaxis demonstration project

48. XVI International AIDS Conference: Part 1

49. Roundtable. Who should be providing HIV care?

50. Antiretroviral rounds. Putting resistance to work

Catalog

Books, media, physical & digital resources